Drug Profile
L 0026
Alternative Names: F 10171Latest Information Update: 12 Dec 2006
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antithrombotics
- Mechanism of Action Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Thrombosis
Most Recent Events
- 14 Mar 2000 No-Development-Reported for Coronary artery restenosis in France (Unknown route)
- 14 Mar 2000 No-Development-Reported for Thrombosis in France (Unknown route)
- 29 Aug 1996 Phase-I clinical trials for Coronary artery restenosis in France (Unknown route)